You'll see more capacity we don't announce, layered into volume we ship
Two pharmaceutical giants, Novo Nordisk and Eli Lilly, have reported extraordinary earnings this quarter, carried forward by a class of drugs that has quietly rewritten the terms of how modern medicine addresses weight and metabolic health. The numbers are staggering — billions in revenue, triple-digit growth — yet the deeper story is one of scarcity meeting desire, and of two companies racing to determine whether a medical breakthrough becomes a broadly shared benefit or a privilege rationed by insurance coverage. The question these earnings raise is not merely financial; it is about who gets access to transformation, and on whose terms.
- Demand for GLP-1 weight-loss and diabetes drugs has outpaced all projections, with Wegovy alone surging 200% year-over-year to $1.37 billion in a single quarter.
- Supply constraints are acting as a hard ceiling on growth — Novo Nordisk is rationing higher doses and blocking new prescriptions to protect existing patients, with no clear timeline for relief.
- Eli Lilly is moving aggressively to avoid the same bottleneck, with CEO David Ricks signaling undisclosed manufacturing expansions designed to flood supply channels before Mounjaro's weight-loss approval lands.
- A coverage war is quietly unfolding as employers and insurers weigh the cost of these drugs against their clinical value — several pulled coverage this year, but 2024 projections suggest employer coverage could double.
- Both companies are deploying sales and wellness infrastructure to keep insurers and employers committed, understanding that manufacturing capacity alone will not determine who wins this market.
Novo Nordisk and Eli Lilly both reported blockbuster third-quarter results this week, driven by surging sales of GLP-1 drugs — medications that slow digestion and boost insulin production — even as both companies struggle to produce enough of them to meet demand.
Novo's weight-loss injection Wegovy brought in $1.37 billion for the quarter, a 200 percent increase from the prior year, while its diabetes drug Ozempic pushed combined quarterly revenue to $4.8 billion. Across the first nine months of 2023, Novo's GLP-1 portfolio grew 60 percent overall, with Wegovy climbing 467 percent. The numbers reflect a genuine shift in how Americans approach weight management — these drugs deliver results that older treatments simply could not. But relentless demand has run headlong into constrained supply. Novo is rationing higher doses and prioritizing existing patients over new prescriptions, with no timeline offered for when that bottleneck might ease.
Eli Lilly finds itself in a more forward-leaning position. Mounjaro generated $1.41 billion in Q3 from its diabetes indication alone, and FDA approval for a standalone weight-loss use is expected before year's end. CEO David Ricks signaled to investors that the company is mobilizing multiple manufacturers beyond what has been publicly announced, intent on building supply before demand fully arrives.
Beyond manufacturing, both companies are fighting a quieter battle over insurance and employer coverage. Several major employers pulled coverage this year as costs rose, but surveys suggest larger companies are increasingly willing to pay, and coverage is projected to double in 2024. Novo has made employer retention a priority this enrollment season, pairing drug access with wellness programs and care support. More than 45 million patients with obesity now have some form of coverage for this drug class — a meaningful milestone, but also a measure of how much remains unresolved.
The real stakes are not quarterly earnings. They are whether these drugs become a standard of care or a luxury good — and whether the companies that created them can hold together the fragile coalition of insurers and employers long enough for supply to catch up with the scale of human need.
Two pharmaceutical giants reported blockbuster earnings this week on the back of a drug class that has captured the public imagination and reshaped the weight-loss market. Novo Nordisk and Eli Lilly both saw their stock prices climb on Thursday as they announced third-quarter results driven by surging sales of GLP-1 drugs — medications that mimic a hormone slowing digestion and boosting insulin production — despite a persistent problem: they cannot make enough of them.
Novo's weight-loss injection Wegovy brought in $1.37 billion in the third quarter alone, a 200 percent jump from the same period last year. Combined with sales of its diabetes drug Ozempic, the two products generated $4.8 billion in quarterly revenue. Over the first nine months of 2023, Novo's entire GLP-1 portfolio grew 60 percent, with Wegovy specifically climbing 467 percent. The numbers reflect an unprecedented shift in how Americans approach weight management. These drugs deliver total body weight loss that older medications in the class simply could not match, and demand has been relentless.
But relentless demand has collided with constrained supply. Novo continues to ration production of both Wegovy and Ozempic in higher doses, prioritizing patients already on the medications over new prescriptions. The company's North America executive vice president, Doug Langa, acknowledged the bottleneck but offered no timeline for relief. This supply crunch is the price of success — it has also become a ceiling on growth until manufacturing capacity catches up.
Eli Lilly is in a different position. Its diabetes drug Mounjaro generated $1.41 billion in the third quarter from the diabetes indication alone, and the company is bracing for what comes next. The FDA is expected to approve Mounjaro as a standalone weight-loss drug by year's end, and Lilly is already ramping up production in anticipation. CEO David Ricks told investors the company is not satisfied with its current capacity announcements. "You'll see more — some we don't announce — that we'll just layer into the volume we ship," he said, signaling that Lilly is mobilizing multiple manufacturers to boost supply before demand explodes.
The two companies are now locked in a race not just to manufacture more drugs, but to secure their place in the insurance and employer coverage landscape. This year, several major employers and organizations pulled coverage as costs spiked, but recent surveys show larger companies are more willing to pay. Coverage is expected to double in 2024. Novo Nordisk has made employer retention a priority during this year's health benefits enrollment season, deploying sales representatives to pitch wellness programs and care support alongside the drugs themselves. The company noted in a statement that more than 45 million patients with obesity now have access to this drug class through government and commercial plans — a sign of expanding coverage, but also a reminder of how much is still at stake.
The battle ahead is not just about manufacturing capacity or quarterly earnings. It is about whether these drugs will become standard care or remain a luxury good available only to those whose insurers agree to pay. Both Novo and Lilly are betting that if they can keep employers and insurers on board, the supply constraints will eventually ease and the real market expansion can begin.
Citações Notáveis
We're not at all happy with the capacity we've announced already. You'll see more — some we don't announce — that we'll just layer into the volume we ship.— David Ricks, CEO of Eli Lilly
More than 45 million patients with obesity have access to this therapy class, which represents a trend of expanded coverage in government healthcare and commercial plans.— Novo Nordisk statement to Yahoo Finance
A Conversa do Hearth Outra perspectiva sobre a história
Why does supply matter so much if demand is already this strong?
Because Novo can't convert demand into revenue if it can't make the drug. Right now they're choosing to serve existing patients rather than take on new ones. That's leaving money on the table — and giving Lilly an opening.
So Lilly has a supply advantage?
Not yet, but they're building one. Mounjaro is still just approved for diabetes, so they have breathing room before the weight-loss indication hits. They're using that time to line up manufacturers and scale up. By the time the FDA approves it for weight loss, they want to be ready.
What's the employer coverage piece about?
Insurance companies and employers decide whether to pay for these drugs. Some pulled coverage this year because the cost was too high. If employers stop covering Wegovy or Mounjaro, patients either pay out of pocket or don't take the drug at all. Both companies lose.
Is that likely to happen?
The opposite, actually. Surveys show bigger employers are warming to coverage, and it's expected to double next year. But Novo and Lilly aren't taking chances. They're actively selling employers on the idea that these drugs are worth the cost.
What's the long game here?
Whoever can manufacture at scale and keep insurers happy wins the market. Right now both companies are supply-constrained, so they're competing on access and trust. Once manufacturing catches up, the real competition begins.